medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2014, Number 1

<< Back Next >>

An Med Asoc Med Hosp ABC 2014; 59 (1)

Evaluation of the efficacy and safety of topical and oral treatments on hormonal and androgenetic alopecia

Espinosa BJ, Rentería CJC, Alejo GJA

Language: Spanish
References: 35
Page: 8-15
PDF size: 362.80 Kb.


ABSTRACT

Background: The combination of oral finasteride and dutasteride with topical minoxidil is currently widely used in the treatment of androgenetic alopecia. However, few studies –with the exception of those carried out in animals– have shown the effectiveness and safety of the combination of several treatment models. In this study, the efficacy and safety of applying topical minoxidil and an oral medication like finasteride and dutasteride scheme over a period of 65 weeks were evaluated. Methods: This is a nonrandomized, unblinded clinical trial; the assessment was made ​​by the attending physician at each visit, with the help of the inspection of sequential shots. An analysis at the end of the study of the digitized images by comparing their histograms was performed. Results: Through the analysis conducted, we identified only three (6.8 %) patients whose changes were not significant. Regarding the safety of the treatments used in this study, only one patient reported sexual dysfunction problems; a determination of PSA was indicated. Conclusions: The results suggest that the combination of topical and oral treatment regimens promotes the growth of new hair. Likewise, the assessment of their effectiveness by analyzing digitized images provided quantitative data that allowed comparing different groups of patients; no statistically significant differences were found between them.


REFERENCES

  1. 1.Stough D, Stenn K, Haber R, Parsley WM, Vogel JE, Whiting DA et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clinic Proceedings. 2005; 80: 1316-1322.

  2. 2.Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Reviews in Molecular Medicine. 2002; 4: 1-11.

  3. 3.Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999; 341: 491-497.

  4. 4.Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia after application of 5 and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999; 41: 717-721.

  5. 5.Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974; 186: 1213-1215.

  6. 6.Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999; 41: 550-554.

  7. 7.Sawaya ME, Price VH. Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997; 109: 296-300.

  8. 8.Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001; 144: 297-304.

  9. 9.Sinclair RD, Dawber RP. Androgenetic alopecia in men and women. Clin Dermatol. 2001; 19: 167-78.

  10. 10.Hamilton JB. Patterned loss of hair in man: types and incidence. Annals of the New York Academy of Sciences. 1951; 53: 708-728.

  11. 11.Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2001; 45: S70-80.

  12. 12.Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977; 97: 247-254.

  13. 13.Cotsarelis G, Millar SE. Towards a molecular understanding of hair loss and its treatment. Trends Mol Med. 2001; 7: 293-301.

  14. 14.Whiting D. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993; 28: 755-763.

  15. 15.Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG et al. A randomized, placebo-controlled trial of 5 and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004; 50: 541-553.

  16. 16.Whiting DA, Waldstreicher J. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999; 4: 282-284.

  17. 17.Bunagan MJKS. Medical treatment of hair loss. In: Pathomvanich D, Imagawa K et al. Hair restoration surgery in Asians. 1st ed. Springer; 2010. pp. 65-69.

  18. 18.Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010; 63: 252-258.

  19. 19.Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010; 146: 1141-1150.

  20. 20.Otberg, N, Restrepo I, Shapiro R. Possibilities and limitations for reversal of age-related hair loss. In: Trüeb RM, Tobin DJ et al. Aging hair. Berlin: Springer; 2010. pp. 193-205.

  21. 21.Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol. 2006; 55: 71-74.

  22. 22.Diggle P, Heagerty P, Liang K-Y, Zeger S. Analysis of longitudinal data. 2nd ed. USA: Oxford University Press; 2002.

  23. 23.Norwood O. Male pattern baldness: classification and incidence. South Med J. 1975; 68: 1359-1365.

  24. 24.Gibbons RD, Fiedler-Weiss VC, West DP, Lapin G. Quantification of scalp hair –a computer aided methodology. J Invest Dermatol. 1986; 86: 78-82.

  25. 25.Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin. 1996; 14: 713-721.

  26. 26.Siegel S, Castellan NJ. Nonparametric statistics for the behavioral sciences. New York: McGraw Hill; 1988.

  27. 27.Burton JL, Marshall A. Hypertrichosis due to minoxidil. Br J Dermatol. 1979; 101: 593-595.

  28. 28.Zappacosta AR. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med. 1980; 303: 1480-1481.

  29. 29.Han JH, Kwon OS, Chung JH, Cho KH, Eun HC, Kim KH. Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. J Dermatol Sci. 2004; 34: 91-98.

  30. 30.Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004; 150: 186-194.

  31. 31.Kaufman K. Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin. 1996; 14: 697-711.

  32. 32.Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004; 63: 709-715.

  33. 33.Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006; 55: 1014-1023.

  34. 34.Diani AR, Mulholland MJ, Shull KL, Kubicek MF, Johnson GA, Schostarez HJ et al. Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab. 1992; 74: 345-350.

  35. 35.Hoffmann R. TrichoScan: a novel tool for the analysis of hair growth in vivo. J Investig Dermatol Symp Proc. 2003; 8 (1): 109-115.




2020     |     www.medigraphic.com